K. Rajasekaran

Papers

1

Total Citations

2

H-Index

1

About

Dr. K. Rajasekaran is a leading oncologic surgeon whose work centers on de-intensification strategies for HPV-related oropharyngeal cancers, with a particular focus on transoral robotic surgery (TORS). His most impactful contribution, detailed in a 2022 Phase II study, demonstrates that carefully selected patients with p16+ oropharyngeal squamous cell carcinoma can safely undergo volume and dose reduction of adjuvant therapy following TORS and neck dissection, thereby minimizing long-term treatment toxicities without compromising oncologic outcomes. This work has garnered early attention with 2 citations, reflecting its emerging influence in reshaping standard-of-care protocols. Dr. Rajasekaran’s research bridges surgical innovation and personalized medicine, offering a paradigm shift away from aggressive chemoradiation toward a more tailored, function-preserving approach. His findings are particularly relevant for students and clinicians exploring de-escalation trials, as they provide a rigorous framework for balancing cure rates with quality of life. By championing evidence-based de-intensification, Dr. Rajasekaran is helping define the next generation of head and neck cancer management.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma
2 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 16

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago